Proprietary platforms
At ReiThera, we develop and manufacture advanced genetic vaccines and biotherapeutics using proprietary platform technologies designed for safety, scalability, and clinical impact. Our platforms – MVA and GRAd – support the full development lifecycle, from early design to GMP production, accelerating the path from lab to clinic.
MVA Platform
ReiThera’s MVA platform is a proven viral vector for vaccines and immunotherapies. It offers excellent safety, manufacturing flexibility in both suspension and adherent systems, and validated GMP processes—ideal for infectious diseases, oncology, and personalized medicine.
GRAd Platform
The GRAd platform is a next-generation adenoviral vector derived from a rare gorilla adenovirus. With low seroprevalence, strong immunogenicity, and thermostability, it enables scalable production and potent immune responses—ideal for vaccines and cancer immunotherapy.
ReiCell-AAV
ReiCell-AAV is a proprietary HEK293 suspension cell line optimized for high-yield AAV manufacturing. Designed for regulatory compliance, it supports efficient transfection, scalable production, and consistent purity—powering gene therapy programs from preclinical stages to commercial supply.
Capabilities
ReiThera offers fully integrated services spanning Technology Development, Process Development, and GMP Manufacturing. From early-stage vector design to clinical-grade production, our end-to-end capabilities ensure a seamless, scalable path to market for genetic vaccines and advanced therapies.
Built for Clinical and Commercial Success
With end-to-end capabilities under one roof, ReiThera provides:
Seamless scale-up
from process development to GMP
Full control of upstream, downstream, and fill-finish operations
Manufacturing solutions tailored for early-stage studies through to market supply
Our facility
ReiThera’s GMP facility is a cutting-edge site for viral vector and biologics manufacturing. It features large-scale bioreactors, advanced cleanrooms, and aseptic filling capabilities, supporting end-to-end development and production under the highest quality standards for both clinical and research applications.